Executive summary The Stanford–Lancet Commission on the North American Opioid Crisis
was formed in response to soaring opioid-related morbidity and mortality in the USA and …

Background Harm reduction and treatment programmes are essential for reducing harms for
people who inject drugs (PWID). We aimed to update estimates from a 2017 review of global …

Abstract Background The United States overdose crisis continues unabated. Despite efforts
to increase capacity for treating opioid use disorder (OUD) in the US, how actual treatment …

Background Opioid use disorder (OUD) and mental disorders are major public health issues
and comorbidity is common. Among people with OUD, comorbid mental disorders are …

As the USA faces a worsening overdose crisis, improving access to evidence-based
treatment for opioid use disorder (OUD) remains a policy priority. Federal regulatory …

Background Opioid dependence is associated with substantial health and social burdens,
and opioid agonist treatment (OAT) is highly effective in improving multiple outcomes for …

Background Drug-related death (DRD) rate in Scotland, UK, has increased rapidly to one of
the highest in the world. Our aim was to examine the extent to which opioid-agonist therapy …

Overdose mortality has continued to rise in North America and across the globe in people
who use drugs. Current harm reduction strategies such as supervised consumption sites …

There is a growing recognition in the fields of public health and medicine that social
determinants of health (SDOH) play a key role in driving health inequities and disparities …

Objective Supraphysiologic doses of anabolic androgenic steroids (AAS) are widely used to
improve body image and sport performance goals. These substances can easily be …